ARO8 Antibody

What is ARO8 Antibody and what is its primary target?

ARO8 Antibody is a rabbit polyclonal antibody specifically targeting the ARO8 protein from Saccharomyces cerevisiae (Baker's yeast). The antibody recognizes recombinant Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ARO8 protein. This antibody has been identified with Entrez Gene ID 852672 and UniProt Number P53090 .

What are the validated applications for ARO8 Antibody?

ARO8 Antibody has been validated for two primary research applications: Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blot (WB) . These techniques are fundamental in protein detection and quantification experiments, making this antibody particularly valuable for yeast protein studies, metabolic pathway investigations, and expression system analyses.

What are the optimal storage conditions for maintaining ARO8 Antibody activity?

For maximum stability and activity retention, ARO8 Antibody should be stored at either -20°C or -80°C . Storage temperature consistency is critical, as temperature fluctuations can compromise antibody functionality. To preserve antibody integrity, it's recommended to aliquot the antibody upon receipt to minimize freeze-thaw cycles, which can lead to protein denaturation and reduced binding capacity.

What controls are provided with ARO8 Antibody for experimental validation?

ARO8 Antibody typically comes with two essential controls for experimental validation:

• 200μg antigens (used as positive control) - enables confirmation of specific binding

• 1ml pre-immune serum (used as negative control) - establishes baseline non-specific binding

These controls are crucial for establishing experimental validity and confirming antibody specificity in research applications.

What are the source organism and isotype specifications for ARO8 Antibody?

ARO8 Antibody is derived from rabbit (source/host organism) and belongs to the IgG isotype class . The antibody undergoes antigen affinity purification to enhance specificity and reduce background binding. This polyclonal antibody maintains species reactivity specific to yeast targets.

How can researchers optimize ARO8 Antibody for Western Blot applications?

Optimizing ARO8 Antibody for Western Blot applications requires systematic parameter adjustment:

• Sample preparation: For yeast samples, employ glass bead disruption (0.5mm beads, 6 cycles of 30-second vortexing with 30-second ice incubation) or enzymatic cell wall digestion (lyticase treatment at 25U/ml for 30 minutes at 30°C) to ensure complete protein extraction.

• Blocking optimization: Test multiple blocking agents:

  • 5% non-fat milk in TBST (most common)

  • 3-5% BSA in TBST (reduces background for phosphoprotein detection)

  • Commercial blockers (for specialized applications)

• Antibody dilution optimization: Create a dilution series (1:100, 1:200, 1:500, 1:1000) to determine the optimal signal-to-noise ratio for your specific experimental conditions.

• Incubation conditions: Compare room temperature incubation (1-2 hours) with 4°C overnight incubation to identify conditions yielding maximum specific signal with minimal background.

• Signal enhancement strategies: For low-abundance targets, consider signal amplification systems similar to those used with other antibodies to enhance detection sensitivity while maintaining specificity .

What methodological approaches are recommended for validating ARO8 Antibody specificity?

Comprehensive validation of ARO8 Antibody specificity should incorporate multiple complementary approaches:

• Genetic validation: Test antibody performance in ARO8 knockout/knockdown yeast strains compared to wild-type strains. Absence of signal in knockout samples provides definitive evidence of specificity.

• Peptide competition assay: Pre-incubate ARO8 Antibody with excess purified target protein (5-10X molar excess) before application to samples. Specific binding should be significantly reduced or eliminated.

• Cross-reactivity assessment: Test the antibody against closely related proteins to determine specificity boundaries. This is particularly important when exploring use in non-yeast systems.

• Multiple detection techniques: Confirm binding specificity using orthogonal methods (ELISA, immunoprecipitation, immunohistochemistry) to strengthen confidence in antibody performance.

• Mass spectrometry validation: Perform immunoprecipitation followed by mass spectrometry to identify all proteins captured by the antibody, enabling definitive confirmation of target specificity.

Similar validation strategies have proven effective for confirming antibody specificity in other research contexts, including clinical studies of antibody responses .

What are the critical parameters for troubleshooting inconsistent ELISA results with ARO8 Antibody?

When encountering variability in ELISA results using ARO8 Antibody, systematically evaluate these parameters:

• Antigen coating optimization:

  • Test multiple coating buffers (carbonate buffer pH 9.6, PBS pH 7.4)

  • Optimize coating concentration (typically 1-10 μg/ml)

  • Evaluate coating temperature and duration (4°C overnight vs. 37°C for 1-2 hours)

• Blocking protocol refinement:

  • Compare blocking agents (1-5% BSA, casein, commercial blockers)

  • Optimize blocking duration (1-2 hours at room temperature)

  • Ensure complete well coverage to prevent non-specific binding

• Antibody dilution and incubation:

  • Establish a standard curve with 2-fold serial dilutions

  • Test multiple incubation temperatures (room temperature vs. 37°C)

  • Optimize incubation duration (1-3 hours)

• Washing stringency:

  • Adjust wash buffer composition (PBS-T with 0.05-0.1% Tween-20)

  • Optimize number of wash cycles (3-6 washes)

  • Standardize washing technique (automated washer vs. manual washing)

• Detection system considerations:

  • Compare colorimetric (TMB, ABTS) vs. chemiluminescent detection

  • Optimize substrate incubation time

  • Ensure proper plate reader calibration

Similar approaches have been successfully applied in antibody testing protocols for clinical studies with low-titer antibodies .

What factors affect the stability and shelf-life of ARO8 Antibody preparations?

Multiple factors influence ARO8 Antibody stability:

• Storage temperature: Maintain consistent storage at -20°C or -80°C as specified . Temperature fluctuations significantly accelerate antibody degradation.

• Freeze-thaw cycles: Each freeze-thaw cycle can reduce antibody activity by 5-20%. Create single-use aliquots upon receipt to minimize this effect.

• Buffer composition effects:

  • Glycerol (typically 25-50%) prevents freezing damage

  • Carrier proteins (0.1-1% BSA) stabilize dilute antibody preparations

  • Preservatives (0.02-0.05% sodium azide) prevent microbial growth

  • pH stability (optimal range: pH 6.5-8.0)

• Contamination prevention:

  • Use sterile technique when handling antibody solutions

  • Avoid introducing particulates or microorganisms

  • Consider adding protease inhibitors if contamination is suspected

• Physical stressors:

  • Minimize exposure to light, especially for conjugated antibodies

  • Avoid vigorous mixing or vortexing, which can denature antibody proteins

  • Prevent prolonged exposure to room temperature

• Chemical stability factors:

  • Oxidation from exposure to air can degrade antibody performance

  • Heavy metal contamination can accelerate degradation

  • Detergent concentration affects stability in working solutions

Similar storage principles have been applied to preserve antibody activity in clinical research settings .

What methodologies are available for epitope mapping of ARO8 Antibody?

Comprehensive epitope characterization can be approached through multiple complementary techniques:

• Peptide array analysis:

  • Generate overlapping 15-20 amino acid peptides spanning the ARO8 sequence

  • Screen array with ARO8 Antibody to identify reactive peptides

  • Refine epitope boundaries with shorter peptides in regions of interest

• Mutation analysis approaches:

  • Create alanine scanning mutants, systematically replacing original residues

  • Express mutant proteins and test antibody binding by ELISA or Western blot

  • Identify critical binding residues where mutations abolish antibody recognition

• Structural analysis techniques:

  • Hydrogen-deuterium exchange mass spectrometry (HDX-MS) to identify protected regions

  • X-ray crystallography of antibody-antigen complexes for atomic-level interaction mapping

  • Computational epitope prediction algorithms to guide experimental design

• Competitive binding assays:

  • Develop competition ELISA with defined peptide fragments

  • Measure inhibition constants (Ki) to quantify binding affinity

  • Map binding regions through systematic competition studies

These approaches can provide valuable insight into antibody specificity and cross-reactivity potential, similar to methods used in characterizing antibody binding in therapeutic applications .

What considerations should researchers make when adapting ARO8 Antibody for cross-species applications?

When exploring ARO8 Antibody applications beyond yeast systems:

• Sequence homology analysis:

  • Perform BLASTP alignment of ARO8 across species of interest

  • Focus on conserved regions as potential cross-reactive epitopes

  • Quantify percent identity and similarity in potential binding regions

• Epitope conservation assessment:

  • Use epitope prediction algorithms to identify likely binding regions

  • Compare these regions across species for conservation

  • Consider structural homology in addition to sequence identity

• Experimental validation strategy:

  • Begin with Western blot using purified recombinant proteins from target species

  • Include positive control (yeast ARO8) alongside target species samples

  • Gradually progress to more complex samples (cell lysates, tissue extracts)

• Optimization for cross-species application:

  • Adjust extraction conditions to preserve epitope structure in new species

  • Modify blocking conditions to reduce species-specific background

  • Consider pre-adsorption with irrelevant proteins from target species

• Complementary validation approaches:

  • Confirm antibody specificity with genetic models when available

  • Use mass spectrometry to verify target identity in immunoprecipitation studies

  • Compare results with alternative detection methods when possible

How does affinity purification impact ARO8 Antibody performance characteristics?

The antigen affinity purification of ARO8 Antibody significantly influences performance characteristics:

This purification approach enhances experimental reproducibility while maintaining the advantages of polyclonal recognition, similar to purification strategies employed in other antibody research applications .

What are the comparative advantages of polyclonal versus monoclonal approaches for ARO8 protein detection?

Understanding the trade-offs between antibody types is essential for experimental design:

The currently available ARO8 Antibody is polyclonal , offering advantages in recognition of multiple epitopes and signal strength, particularly valuable for initial characterization studies.

What quantitative methods can assess ARO8 Antibody cross-reactivity profiles?

Comprehensive cross-reactivity assessment requires quantitative approaches:

• Protein microarray analysis:

  • Screen binding against arrays containing multiple yeast proteins

  • Include homologs from other species to assess cross-species reactivity

  • Quantify relative binding affinity to each potential target

• Surface Plasmon Resonance (SPR) analysis:

  • Determine binding kinetics (kon and koff rates) for primary target

  • Compare with binding parameters for potential cross-reactive proteins

  • Calculate affinity constants (KD) to quantify relative binding strength

• Competitive binding ELISA:

  • Coat plates with ARO8 protein

  • Pre-incubate antibody with varying concentrations of potential cross-reactive proteins

  • Measure inhibition of binding to determine relative affinity

• Immunoprecipitation-Mass Spectrometry (IP-MS):

  • Perform IP with ARO8 Antibody from complex protein mixtures

  • Identify all captured proteins by mass spectrometry

  • Quantify relative abundance of specific vs. non-specific targets

• Epitope conservation analysis:

  • Map the specific binding region through epitope mapping techniques

  • Conduct sequence similarity searches focused on the epitope region

  • Calculate percent identity within epitope regions of potential cross-reactive proteins

These approaches provide complementary information about antibody specificity and can be applied in combination to create a comprehensive cross-reactivity profile.

How can researchers optimize dilution protocols for novel ARO8 Antibody applications?

Systematic dilution optimization involves:

• Initial broad-range screening:

  • Prepare logarithmic dilution series (1:100 to 1:10,000)

  • Test against positive control samples with known target concentration

  • Identify the range where signal remains proportional to target concentration

• Fine-tuning dilution strategy:

  • Narrow testing to 2-fold dilution series within the effective range

  • Calculate signal-to-noise ratio for each dilution

  • Determine the dilution yielding maximum specific signal with acceptable background

• Application-specific considerations:

  • Western blot: Lower dilutions (1:100 to 1:1,000) typically optimal

  • ELISA: Higher dilutions (1:1,000 to 1:5,000) often sufficient

  • Immunoprecipitation: Lower dilutions (1:50 to 1:200) generally required

• Sample matrix optimization:

  • Test antibody performance in buffers matching experimental conditions

  • Evaluate effects of detergents, salts, and carrier proteins on binding

  • Adjust dilution based on matrix effects

• Statistical validation:

  • Perform replicate experiments (minimum n=3)

  • Calculate coefficient of variation at each dilution

  • Select dilution with consistent performance (CV <15%)

Similar dilution optimization approaches have been successfully applied in other antibody-based research protocols .